Ken Griffin
APUS

Ken Griffin’s Apimeds Pharmaceuticals US APUS Stock Holding History

Ken Griffin’s Portfolio APUS Stock Details APUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,336
Closed -$23.5K – 14570
2025
Q2 		$23.5K Buy
+1,336
New +$24.1K ﹤0.01% 12066

Other funds holding APUS

HTHT
Hemenway Trust Hemenway Trust Salem, New Hampshire $1.43B AUM 37.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Ken Griffin's APUS Position: Q3 2025 in Review

Ken Griffin sold out of Apimeds Pharmaceuticals US (APUS) in Q3 2025, closing a stake of 1,336 shares — an estimated $23.5K sold.

Ken Griffin first reported a position in APUS in Q2 2025 and held it in 1 quarter. The position peaked at $23.5K in Q2 2025. 8 funds tracked by Wall St. Rank hold APUS as of Q3 2025.

  • Ken Griffin reported no remaining Apimeds Pharmaceuticals US position as of Q3 2025 after selling out during the quarter.
  • Ken Griffin sold 1,336 Apimeds Pharmaceuticals US shares in Q3 2025, an estimated $23.5K.
  • Ken Griffin first reported a position in Apimeds Pharmaceuticals US in Q2 2025 and held it in 1 quarter.
  • Ken Griffin's Apimeds Pharmaceuticals US position peaked at $23.5K in Q2 2025.
  • 8 funds tracked by Wall St. Rank held Apimeds Pharmaceuticals US as of Q3 2025.

Based on Citadel Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.